<DOC>
	<DOCNO>NCT01877694</DOCNO>
	<brief_summary>The purpose study evaluate microbiological clinical efficacy Auriclosene compare vehicle bacterial conjunctivitis . Adults child one year age old bacterial conjunctivitis least one eye may eligible . Subjects randomly assign receive either Auriclosene Ophthalmic Solution Vehicle Ophthalmic Solution .</brief_summary>
	<brief_title>Efficacy Safety Auriclosene ( NVC-422 ) Treatment Bacterial Conjunctivitis</brief_title>
	<detailed_description>This randomize ( 1:1 ) double-masked , vehicle-controlled , multi-center , parallel group study two treatment arm : Auriclosene Ophthalmic Solution 0.3 % ( `` Auriclosene '' ) Auriclosene Vehicle ( `` Vehicle '' ) . Subjects meet inclusion/exclusion criterion enrol study , randomize evaluate 3 visit : - Visit 1 : Screening , Day 1 - Visit 2 : Day 3 ( Â±1 ) - Visit 3 : Day 5 ( +1 ) Test Cure/Exit IP dose OU ( eye ) QID 4 day . Microbiological specimen collect eye visit . Visual Acuity assess OU visit well rating ocular sign : lid erythema swelling , bulbar palpebralconjunctival injection , conjunctival discharge/exudate .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 year age old Bulbar conjunctival injection Conjunctival discharge/exudate Signs symptoms bacterial conjunctivitis least one eye 3 day less Other inclusion criterion per protocol Suspected fungal , viral , Chlamydia Acanthamoeba coinfection base clinical diagnosis Any drug treatment either eye current episode bacterial conjunctivitis prior study enrollment Other exclusion criterion per protocol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>pink eye</keyword>
</DOC>